Eloxx Pharmaceuticals, Inc., based in Arlington, Massachusetts, has announced the pricing of its public offering aimed at raising $66 million. The offering includes 2,975,000 shares of common stock priced at $11.00 each and 3,025,000 pre-funded warrants at $10.99 each. The company anticipates that the shares will start trading on the Nasdaq Capital Market under the ticker symbol ELOX on June 9, 2026, with the offering expected to close on June 10, 2026, pending customary conditions. Leerink Partners and Guggenheim Securities are acting as joint bookrunning managers, while LifeSci Capital serves as a passive bookrunner. A registration statement related to this offering was filed with the Securities and Exchange Commission (SEC) and became effective on June 8, 2026. This public offering represents a significant step for Eloxx as it prepares for its uplisting to Nasdaq, reflecting its commitment to advancing its clinical-stage biopharmaceutical developments.